Professor Ian MacNeish
Iain McNeish is Professor of Oncology and Head of the Division of Cancer within the Department of Surgery and Cancer. He is also the Director of the Ovarian Cancer Action Research Centre and theme lead for Surgery and Cancer in the Imperial NIHR Biomedical Research Centre (BRC). His research focusses on ovarian cancer, specifically developing improved therapies through improved understanding of disease biology. He leads the BriTROC translational research collaborative that first described copy number signatures in ovarian high grade serous carcinoma (HGSC) as a possible prognostic and predictive biomarker. His group has also recently developed novel transplantable murine models of HGSC using CRISPR/Cas9 gene editing technology to allow investigation of novel therapies in an immunocompetent model. He has also led key clinical trials, including ARIEL2, the study to incorporate genomic assays as potential predictive biomarkers of response to PARP
inhibitor therapy in ovarian cancer.
Dr Ina Jürgenliemk-Schulz
Ina Jürgenliemk-Schulz graduated in Biology at the University of Bochum, Germany in 1983. After medical study she received her MD from the same University in 1989 and completed her PhD in 1990. She is staff radiation oncologist at UMC Utrecht in The Netherlands. She is specialized
in external beam radiotherapy and brachytherapy for gynecologic primary tumors and nodal disease.
Since 2005 she is active member of the gyn working group in GEC-ESTRO including the EMBRACE study group. With respect to technical developments she was leading physician during the implementations of MRI guided brachytherapy and of MR Linac at UMCU. From April 2020 to May 2022 she was chair of GEC-ESTRO and currently is the past-chair.
Professor Rene Pareja
Dr. René Pareja is a Gynecologist and Obstetrician, graduated from Universidad Pontificia Bolivariana in Medellín, Colombia in 2000; he finished his training in Gynecologic Oncology in 2003, from Pontificia Universidad Javeriana and Instituto Nacional de Cancerología in Bogotá, Colombia. He is a minimally invasive surgeon, graduated from Corporación de Estudios de la Salud (CES) in 2013. He currently works at Astorga Oncology Clinic in Medellín and at National Cancer Institute in Bogotá, Colombia.
Dr. Pareja serves as a reviewer for more than 20 journals. He has authored or co-authored nine book chapters and more than fifty publications in peer-reviewed journals. Currently he is an Associate Editor of the International Journal of Gynaecological Cancer and is a Council member of the International Gynecological Cancer Society Council. He also serves as an international mentor for the Hospital General San Juan de Dios in Guatemala.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, visit www.astrazeneca.com and www.astrazeneca.com.au.